A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (ENLIGHTEN-6)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
Sponsor: Eli Lilly and Company
A observational or N/A phase clinical study on Obesity and Overweight, this trial is actively recruiting participants. The trial is conducted by Eli Lilly and Company and has accumulated 3 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
3 versions recorded-
Apr 18, 2026 — Present [daily]
Recruiting
Phase: PHASE3 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Afula, Israel , Allahābād, India , Almería, Spain , Atlantis, United States , Atlit, Israel , Bangalore, India , Barcelona, Spain , Bayamón, Puerto Rico , Beersheba, Israel and 168 more locations